Sponsored Content
Pharmaceutical Industry
Tyrolean Biotech Company Cyprumed Closes 493 Million Dollar Deal with American MSD
The Innsbruck-based biotechnology company Cyprumed GmbH is making international headlines with a multi-million dollar license deal: Together with the U.S. pharmaceutical group MSD (Merck & Co., Inc.), the company has signed an agreement worth up to 493 million US dollars. The aim is to develop innovative tablet formulations for peptide drugs - a potential game changer in modern drug therapies.
April 15, 2025
Japan's Rohto Pharmaceutical Invests in Austrian Sigmapharm
In a move to enhance pharmaceutical production in Europe, Japan’s Rohto Pharmaceutical has entered into a strategic partnership with the Austrian Sigmapharm Group. The collaboration aims to expand the production and distribution of ophthalmic drugs and medical products across Europe, with Rohto Pharmaceutical investing nearly €30 million in research, development, production, and sales.
September 18, 2024
Swiss Novartis Opens Fastest Cell Culture Facility in Tyrol
Novartis opened a state-of-the-art cell culture facility for the production of monoclonal antibodies in Schaftenau, Tyrol.
June 24, 2024
Japanese Takeda Lays Foundation Stone for "Laboratory of the Future" in Vienna's Urban Lakeside Aspern
In a symbolic act, the foundation stone was laid for Takeda's "Laboratory of the Future" in Vienna's Seestadt Aspern. With an investment of around 120 million euros, the Japanese pharmaceutical giant represents the company's largest investment to date in Austria in a technically and ecologically optimized new building for biopharmaceutical research and development.
September 22, 2023
Austria as a Pharma Industry Location: 50 Million Euro Investment Package for the Life Science Sector
In order to strengthen one of the most important economic sectors of the domestic economy, the pharmaceutical industry, the budget for the funding program "Austrian Life Sciences" was recently presented. Minister of Economics Margarethe Schramböck hopes that this will make Austria more attractive as a business location for life science companies.
April 1, 2022
Austro-French Vaccine Company Valneva's Covid-19 Jab under EU Review
The EU's medicines agency EMA launched an accelerated review of a Covid-19 vaccine by Austro-French biotech firm Valneva. Recently the European Commission agreed to buy as many as 60 million doses of its Covid-19 vaccine. The deal would allow EU member states to purchase almost 27 million doses from Valneva in 2022, and an additional 33 million in 2023.
December 2, 2021
Japanese Life Sciences Corporation Invests More Than 100 Million Euros in Vienna
The Japanese life sciences company Takeda Pharmaceutical Company Limited is investing more than 100 million euros in a new building in Seestadt, Vienna. Read about the massive investment and see a picture of what it is supposed to look like upon completion.
November 18, 2021
Free Coronavirus Antigen Tests in Austria's Pharmacies: How Does It Work and Where Are You Getting Them?
Approximately 450 Austrian pharmacies are now offering free coronavirus antigen tests. Following is how it works and a list of all participating pharmacies.
February 8, 2021
Swiss President Welcomes Kurz
Swiss President Sommaruga and Austria's Chancellor Kurz met near Bern to discuss current topics related to the Covid-19 pandemic and the cooperation between the two countries. Kurz also met with CEOs of leading Swiss pharmaceutical companies to discuss the current vaccine developments.
September 21, 2020
Bottleneck for Influenza Vaccine Is Expected
This year the higher demand in Influenza Vaccine is causing a bottleneck and not everyone who wants to get vaccinated will be. As a result of the COVID-19 crisis, Austrians are more aware of the importance of a vaccine.
August 20, 2020
COVID-19 Drug Made in Austria
Austrian biotech company Apeiron Biologics AG, which is currently working on a drug to treat the coronavirus, announces financing round for the further development of the COVID-19 drug APN01.
May 19, 2020
Austria Becomes Self-sufficient in the Supply of Mouth and Nose Masks
Hygiene Austria LP GmbH, founded only 4 weeks ago by a cooperation of Lenzing AG and Palmers Textil AG with the aim of producing and selling protective masks for the domestic and European market, was made known to a wider public today by the visit of Federal Chancellor Kurz and Minister of Labour Christine Aschbacher, and two weeks ago by the visit of Federal Minister Margarete Schramböck.
May 19, 2020
Pfizer Invests 50 Million Euros in Lower Austria
Pfizer is expanding its site in Orth an der Donau by investing 50 million euros in the construction of new laboratories for an international quality control center for vaccines, the construction of modern office space and the modernization and expansion of the existing production infrastructure. Pfizer already produces two vaccines for worldwide export in Orth an der Donau.
August 28, 2019
Life Sciences Field is Booming in Vienna
Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.
October 14, 2015
Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
August 1, 2014
EU’s Austerity Cuts Adverse to Health
EU’s austerity measures negatively affect citizen’s health, is the result of a health study carried out by “The Lancet”. The Commission was supposed to examine the political effects.
March 27, 2013
Slovakia: CPI Remains Constant
In February, compared with January, consumer prices did not change in total. Increase in prices only in Education, Food and Health Industry.
March 14, 2013
Austria at Medical Fair Asia 2012
Top medical products “made in Austria” at MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA 2012 from September 12 2012 to September 14 2012 in Singapore.
August 20, 2012
U.S. Forest Laboratories Cooperates with Nabriva
The U.S. pharmaceutical company provides funds of $ 25m to the Austrian Nabriva and secures pre-emptory rights.
June 2, 2012
Baxter Enlarges Viennese Site
The U.S. pharmaceutical group makes investments of € 30m in Vienna. The start of operation of a new production facility is planned in 2014.
May 18, 2012
Intercell Completes Equity Private Placement
The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.
May 15, 2012
Intercell Remains in the Loss Area
The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.
May 8, 2012
Canadian Valeant Buys Assets of Gerot Lannach
The Austrian drugmaker Gerot Lannach sells its acetylsalicylic acid business in Russia. The sale price amounts to $ 185m.
March 13, 2012
Sanochemia Announced Scanlux Market Entry in Columbia
The Austrian pharmaceutical company announced the market entry of Scanlux in Columbia. Further approvals are targeted in Costa Rica, El Salvador, Venezuela and Paraguay.
March 7, 2012
Intercell Does Not Leave the Loss zone
The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.
March 6, 2012
Slight Improvement in Sanochemia´s Results
The Austrian pharmaceutical company could increase sales by 12% in the first quarter of 2011/12. Sanochemia could reach small profits again.
February 15, 2012
Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
February 6, 2012
Slightly Positive Results at Sanochemia
The Austrian pharmaceutical company raised revenues by 26%. Profits amount to € 0.7m.
January 26, 2012
Too Little Competition for Energy and Pharmaceuticals
According to the Austrian institute of economic research (WIFO), electricity, energy and pharmaceuticals are too expensive.
January 2, 2012
New Chairman for Intercell’s Supervisory Board
Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.
December 30, 2011
Sanochemia Achieves Turnaround
The Austrian pharmaceutical company could turn net results and EBIT into the profit zone. Sales were up too.
December 19, 2011
Intercell Receives Approval for Vaccine in India
The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.
November 10, 2011
Intercell Still Reports Losses
The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.
November 8, 2011
R&D Expenses on the Rise
The largest Austrian Enterprises increased their budgets for research & development by 9.6% on average. This is slightly beyond the global average (9.3%).
October 24, 2011
Intercell Continues Development of Vaccines
The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.
October 24, 2011
Intercell: EU Invests € 30m in Research Program
The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.
September 29, 2011
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Sanochemia´s Purchase of Alvetra & Werfft Completed
The Austrian pharmaceutical group acquires the former subsidiary again for € 5.2m.
September 21, 2011
Intercell Successfully Completes Vaccine Study in India
The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.
September 16, 2011
Intercell: Restructuring Is Progressing
Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.
August 16, 2011
ugichem Closes € 2m Financing Round
The Tyrolean biotech company secured funding from two major investors and a research grant from the Austrian Research Promotion Agency.
August 9, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Intercell: “We Will Stabilize Our Share Price”
The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.
June 21, 2011
Intercell to Cut Jobs and Research Budget
The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.
June 8, 2011
Sanochemia Confirms the Turnaround and Returns to Profitability
Sanochemia reports a profit and puts the focus on market expansion. Revenue increased by 20 percent year-on-year.
May 13, 2011
Intercell: Sale Is No Longer Ruled Out
The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.
May 11, 2011
Lingelbach New CEO for Intercell
Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.
May 5, 2011
Intercell starts a confirmatory clinical study using the Vaccine Enhancement
Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches
May 4, 2011
Sanochemia: Capital Increase Disappointing
The Austrian pharmaceutical company could not meet its own expectations regarding the capital increase. A strategic investor bailed out.
April 18, 2011
Intercell: Vaccine Development to Suspend
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.
April 11, 2011
Fast News Search
